Sapience Investments LLC Sells 33,344 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Sapience Investments LLC lowered its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 15.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 181,413 shares of the company's stock after selling 33,344 shares during the period. Sapience Investments LLC's holdings in Elanco Animal Health were worth $2,197,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. CoreCap Advisors LLC bought a new stake in Elanco Animal Health in the 4th quarter valued at about $29,000. Jones Financial Companies Lllp boosted its holdings in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares during the period. SRS Capital Advisors Inc. boosted its holdings in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after purchasing an additional 3,411 shares during the period. MRP Capital Investments LLC bought a new stake in Elanco Animal Health in the 4th quarter valued at about $61,000. Finally, Blue Trust Inc. boosted its holdings in Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after purchasing an additional 1,894 shares during the period. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

ELAN stock traded down $0.14 during trading on Tuesday, reaching $13.08. 5,913,007 shares of the company were exchanged, compared to its average volume of 5,062,449. The company has a 50-day moving average of $10.16 and a two-hundred day moving average of $11.44. The company has a market capitalization of $6.50 billion, a price-to-earnings ratio of 32.70, a P/E/G ratio of 2.50 and a beta of 1.49. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The business had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's quarterly revenue was down 1.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.34 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm's stock in a transaction on Friday, March 7th. The stock was purchased at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the transaction, the director now owns 101,459 shares in the company, valued at $1,105,903.10. The trade was a 10.93% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.89% of the company's stock.

Analysts Set New Price Targets

ELAN has been the subject of a number of recent research reports. UBS Group cut their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus boosted their target price on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Monday. Morgan Stanley dropped their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Piper Sandler dropped their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Elanco Animal Health currently has a consensus rating of "Hold" and an average target price of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.